Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2013 08:45 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Announces Strategic Change in Research and Development Programs to Focus on Dilated Cardiomyopathy and Other Rare Disease Indications

Focus shifted to Phase 2b ixCELL-DCM clinical study and the development of ixmyelocel-T for dilated cardiomyopathy, an orphan drug indication. Company to stop enrollment and end Phase 3...
March 18, 2013 16:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Fourth-Quarter and Year-End 2012 Financial Results

ANN ARBOR, Mich., March 18, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
March 12, 2013 16:15 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Host Fourth Quarter 2012 Investor Call on March 18, 2013

ANN ARBOR, Mich., March 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
March 06, 2013 16:15 ET | Source: Aastrom Biosciences, Inc.

Aastrom Board of Directors Names Dominick C. Colangelo President and Chief Executive Officer

ANN ARBOR, Mich., March 6, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
December 12, 2012 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Board of Directors Names Dan Orlando Interim CEO

ANN ARBOR, Mich., Dec. 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
December 10, 2012 09:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Present at the 23rd Annual Oppenheimer Healthcare Conference

ANN ARBOR, Mich., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
November 26, 2012 09:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Board Member Dr. Harold C. Urschel of Baylor University Medical Center Passes Away

ANN ARBOR, Mich., Nov. 26, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
November 20, 2012 09:15 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Present at Therapeutic Area Partnerships Meeting

ANN ARBOR, Mich., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
November 08, 2012 16:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Third-Quarter and Nine-Month 2012 Financial Results

ANN ARBOR, Mich., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe...
November 05, 2012 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom to Host Third Quarter 2012 Investor Call on November 8, 2012

ANN ARBOR, Mich., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...